Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation

Shohei Yamamoto,Ryosuke Matsuno,Y. Sugishita,Ryota Kaneko,Naoko Okamoto,M Koganesawa,S. Fujita,Kosuke Akiyama,Daisuke Toyama,Keiichi Isoyama

Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation

2017

Shohei Yamamoto
Ryosuke Matsuno
Y. Sugishita
Ryota Kaneko
Naoko Okamoto
M Koganesawa
S. Fujita
Kosuke Akiyama
Daisuke Toyama
Keiichi Isoyama

Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation

Keywords:

Cell
Immunology
Progenitor cell
Graft-versus-host disease
Stem cell
Medicine
Thrombomodulin
Haematopoiesis
Gemtuzumab ozogamicin
Transplantation
Myeloid
Leukemia
Monoclonal
Hematopoietic stem cell transplantation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations